Physician profile
Patricia Burch
NPI 1295829851
$8,902.48
in general payments reported to CMS, 2019-2025
41 companies · $933 in 2025
The $933 reported for 2025 was more than what 84% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,148 · 2020: $1,289 · 2021: $2,237 · 2022: $1,238 · 2023: $1,248 · 2024: $811 · 2025: $933.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,991 · Education: $0.79.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,990.73 |
| Education | $0.79 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,143.74 | 2021-2025 | Linzess, Viberzi, Vraylar |
| Glaxosmithkline, LLC. | $861.87 | 2019-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Amgen INC. | $724.87 | 2019-2025 | Evenity, Prolia, Repatha |
| Lilly USA, LLC | $597.33 | 2020-2025 | Mounjaro, Kisunla, Zepbound |
| Boehringer Ingelheim Pharmaceuticals, INC. | $566.79 | 2019-2023 | Jardiance, Ofev |
| Astrazeneca Pharmaceuticals LP | $527.62 | 2020-2025 | Airsupra, Farxiga, Breztri |
| Pfizer INC. | $499.57 | 2019-2024 | |
| Bayer Healthcare Pharmaceuticals INC. | $481.57 | 2021-2025 | |
| Novo Nordisk INC | $449.93 | 2019-2023 | Ozempic, Rybelsus |
| Janssen Pharmaceuticals, INC | $420.06 | 2019-2024 | Spravato |
| Sumitomo Pharma America, INC. | $404.36 | 2023-2025 | Gemtesa |
| Novartis Pharmaceuticals Corporation | $371.93 | 2019-2024 | |
| Daiichi Sankyo INC. | $225.59 | 2019-2023 | Injectafer |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $189.07 | 2019-2022 | |
| Sunovion Pharmaceuticals INC. | $138.31 | 2021-2022 |
Show all 41 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Patricia Burch listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.